RXST
RxSight, Inc.
Overview
RxSight, Inc. manufactures and sells the Light Adjustable Lens (LAL), a premium intraocular lens that can be customized after cataract surgery using an office-based light delivery device, enabling surgeons to optimize patients' vision outcomes postoperatively rather than committing to a fixed lens power before surgery.
RxSight, Inc is a Healthcare company operating in Medical Devices with a $205.3M market cap.
Most recent reported earnings: Q2 FY2026 (Aug 5, 2026).
19 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Extracted from SEC 10-K filing, 2026-06-21.
Transcripts
Recent earnings calls
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
- Q1 FY2026Earnings2026-05-0917 Q&A exchanges
- Q4 FY2025Earnings2026-02-2516 Q&A exchanges
- Q3 FY2025Earnings2025-11-0516 Q&A exchanges
- Q2 FY2025Earnings2025-08-087 Q&A exchanges
- Q1 FY2025Earnings2025-04-0316 Q&A exchanges
- Q4 FY2024Earnings2025-02-2522 Q&A exchanges
- Q3 FY2024Earnings2024-11-0918 Q&A exchanges
- Q2 FY2024Earnings2024-08-0522 Q&A exchanges
- Q1 FY2024Earnings2024-05-0613 Q&A exchanges
- Q4 FY2023Earnings2024-02-2830 Q&A exchanges
- Q3 FY2023Earnings2023-11-1219 Q&A exchanges
- Q2 FY2023Earnings2023-08-0719 Q&A exchanges
- Q1 FY2023Earnings2023-05-1314 Q&A exchanges
- Q4 FY2022Earnings2023-03-0613 Q&A exchanges
- Q3 FY2022Earnings2022-11-078 Q&A exchanges
- Q2 FY2022Earnings2022-08-0810 Q&A exchanges
- Q1 FY2022Earnings2022-05-0915 Q&A exchanges
- Q4 FY2021Earnings2022-03-0813 Q&A exchanges
- Q3 FY2021Earnings2021-11-1011 Q&A exchanges
History
Earnings history
- Q2 FY20262026-08-05EPS— vs $-0.37—Rev— vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-08-05 | — | $-0.37 | — | — | — | — | EODHD |
Source: EODHD. RXST reported actuals as published; sparse fields render as —.
Track Record
SampleSpoken Alpha tracks RXST's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters with 60% positive reaction rate
SampleConsistent execution against consensus with the stock following through is the cleanest signal a guidance regime is calibrated. Worth watching for the inflection where execution deteriorates relative to the bar.
Raised guidance 8 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
Quarterly beats & misses
Sample| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $0.64 | $0.45 | +42.6% | +1.8% | +1.8% |
| Q4 FY2026 | $0.69 | $0.51 | +35.5% | -0.5% | -2.5% |
| Q3 FY2026 | $0.77 | $0.54 | +42.8% | +2.4% | -0.2% |
| Q2 FY2026 | $0.53 | $0.38 | +39.3% | -1.4% | -3.6% |
| Q1 FY2025 | $0.79 | $0.54 | +46.2% | +3.0% | +5.7% |
| Q4 FY2025 | $0.63 | $0.47 | +33.6% | +4.2% | +3.2% |
| Q3 FY2025 | $0.57 | $0.40 | +42.1% | +5.0% | +3.8% |
| Q2 FY2025 | $0.71 | $0.49 | +45.4% | +8.5% | +8.6% |
| Q1 FY2024 | $0.72 | $0.54 | +33.7% | -2.6% | -1.9% |
| Q4 FY2024 | $0.85 | $0.60 | +41.3% | -2.0% | -3.9% |
Guidance change history
Sample- Q1 FY2026Raised2026-04-15
- Q4 FY2026Raised2026-13-15
- Q3 FY2026Raised2026-10-15
- Q2 FY2026Raised2026-07-15
- Q1 FY2025Raised2025-04-15
- Q4 FY2025Raised2025-13-15
- Q3 FY2025Raised2025-10-15
- Q2 FY2025Raised2025-07-15
Top executives
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
- Ronald M Kurtz MdCEO1 yr 4 mo18 callsCurrentSample
CEO since 2025 • 2/4 beats (50%) • last guidance cut Q2 FY2026
- Mark WilterdingCFO5 mo2 callsCurrentSample
CFO since 2026 • 1/2 beats (50%) • guidance suspended Q2 FY2026
- Ilya GoldshlegerCOO4 mono recorded callsCurrentSample
COO since 2026 • 1/2 beats (50%) • guidance suspended Q1 FY2026
- Scott GainesChief Customer Officer6 mono recorded callsCurrentSample
OTHER_C_SUITE since 2025 • 3/4 beats (75%) • last guidance cut Q1 FY2026
- Eric WeinbergSee remarks1 yr 4 mono recorded callsCurrentSample
OTHER since 2025 • 2/4 beats (50%) • guidance suspended Q3 FY2026
- Shelley B ThunenSee remarks2 mo17 callsFormerSample
OTHER since 2025 • 2/4 beats (50%) • guidance suspended Q3 FY2026
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for RXST.
$ curl https://api.spokenalpha.com/v1/companies/RXSTFAQ
Frequently asked about RXST
Where can I find RxSight, Inc.'s (RXST) earnings call transcripts?
Spoken Alpha indexes RXST's earnings call transcripts at https://spokenalpha.com/companies/RXST. Each call links to attributed speakers and parsed analyst Q&A. RxSight, Inc.'s own investor relations page is at https://investors.rxsight.com/.
When was RxSight, Inc.'s most recent earnings call?
RxSight, Inc. (RXST) held its most recent earnings call on 2026-05-09, covering fiscal Q1 2026.
What sector is RXST in?
RxSight, Inc. (RXST) operates in the Healthcare sector (Medical Devices industry).